Literature DB >> 32503858

Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.

Renato Alberto Sinico1,2, Andrea Doria3, Gabriella Moroni4, Mariele Gatto3, Francesco Tamborini5, Silvana Quaglini6, Francesca Radice1,2, Francesca Saccon3, Giulia Frontini5, Federico Alberici7, Lucia Sacchi6, Valentina Binda5, Barbara Trezzi1,2, Augusto Vaglio8, Piergiorgio Messa5.   

Abstract

OBJECTIVES: Short-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year.
METHODS: We considered patients with LN who underwent renal biopsy followed by induction therapy between January 1970 and December 2016. LN was assessed using the International Society of Nephrology/Renal Pathology Society (2003) criteria and the National Institute of Health (NIH) activity and chronicity index. The renal outcome was CKD. Response was defined according to EULAR/European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations: complete: proteinuria <0.5 g/24 hours, (near) normal estimated glomerular filtration rate (eGFR); partial: ≥50% proteinuria reduction to subnephrotic levels, (near) normal eGFR; and no response: all the other cases. Logistic regression analysis was employed for 12-month response and Cox regression for CKD prediction.
RESULTS: We studied 381 patients (90.5% Caucasians). After 12-month therapy, 58%, 26% and 16% of patients achieved complete, partial and no response, respectively, according to EULAR/ERA-EDTA. During a median follow-up of 10.7 (IQR: 4.97-18.80) years, 53 patients developed CKD. At 15 years, CKD-free survival rate was 95.2%, 87.6% and 55.4% in patients with complete, partial and no response at 12 months, respectively (p<0.0001). CKD-free survival rates did not differ between complete and partial responders (p=0.067). Serum creatinine (HR: 1.485, 95% CI 1.276 to 1.625), eGFR (HR 0.967, 95% CI 0.957 to 0.977) and proteinuria at 12 months (HR 1.234, 95% CI 1.111 to 1.379) were associated with CKD, yet no reliable cut-offs were identified on the receiver operating characteristic curve. In multivariable analysis, no EULAR/ERA-EDTA response at 12 months (HR 5.165, 95% CI 2.770 to 7.628), low C4 (HR 1.053, 95% CI 1.019 to 1.089) and persistent arterial hypertension (HR 3.154, 95% CI 1.500 to 4.547) independently predicted CKD.
CONCLUSIONS: Lack of EULAR/ERA-EDTA response at 12 months predicts CKD. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arterial hypertension; lupus nephritis; systemic lupus erythematosus

Year:  2020        PMID: 32503858     DOI: 10.1136/annrheumdis-2020-216965

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

Review 1.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

2.  Chronic kidney disease in Korean patients with lupus nephritis: over a 35-year period at a single center.

Authors:  Howook Jeon; Jennifer Lee; Ji Hyeon Ju; Wan-Uk Kim; Sung-Hwan Park; Su-Jin Moon; Seung-Ki Kwok
Journal:  Clin Rheumatol       Date:  2022-02-18       Impact factor: 2.980

3.  Beyond ISN/RPS Lupus Nephritis Classification: Adding Chronicity Index to Clinical Variables Predicts Kidney Survival.

Authors:  Gabriella Moroni; Giulia Porata; Francesca Raffiotta; Silvana Quaglini; Giulia Frontini; Lucia Sacchi; Valentina Binda; Marta Calatroni; Francesco Reggiani; Giovanni Banfi; Claudio Ponticelli
Journal:  Kidney360       Date:  2021-11-05

4.  Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients.

Authors:  Keqian Du; Xuecheng Zhang; Junmei Feng; Sijie Zhong; Jun Qi; Zhiming Lin
Journal:  Clin Rheumatol       Date:  2022-07-19       Impact factor: 3.650

5.  Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis.

Authors:  Gabriella Moroni; Luca Iaccarino; Mariele Gatto; Francesca Radice; Francesca Saccon; Marta Calatroni; Giulia Frontini; Barbara Trezzi; Margherita Zen; Anna Ghirardello; Francesco Tamborini; Valentina Binda; Vincenzo L'Imperio; Andrea Doria; Augusto Vaglio; Renato Alberto Sinico
Journal:  Lupus Sci Med       Date:  2022-05

6.  Immune gene expression and functional networks in distinct lupus nephritis classes.

Authors:  Alyssa C Gilmore; Hannah R Wilson; Thomas D Cairns; Marina Botto; Liz Lightstone; Ian N Bruce; Herbert Terence Cook; Matthew Caleb Pickering
Journal:  Lupus Sci Med       Date:  2022-01

7.  New Insights Into an Overlooked Entity: Long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort.

Authors:  Eleni Kapsia; Smaragdi Marinaki; Ioannis Michelakis; George Liapis; Petros P Sfikakis; Maria G Tektonidou; John Boletis
Journal:  Front Med (Lausanne)       Date:  2022-04-14

8.  Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort.

Authors:  Eleni Kapsia; Smaragdi Marinaki; Ioannis Michelakis; George Liapis; Petros P Sfikakis; John Boletis; Maria G Tektonidou
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.